Merck Sinks 9.5% in a Week as It Scraps a Blood Cancer Drug and Healthcare Sells Off. Time to Buy?

Merck (MRK) shares dropped 9.5% last week after halting development of a blood cancer drug and a broader healthcare sell-off. The company won a German court case against Halozyme (HALO) but faces patent loss for Keytruda in 2028. Analysts expect 2027 earnings to recover to 2025 levels. Merck's stock is up 27% in 2026.

Original reporting
Published Nov 21, 2026, 10:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 21, 2026, 11:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Merck Sinks 9.5% in a Week as It Scraps a Blood Cancer Drug and Healthcare Sells Off. Time to Buy? — source image
Decision brief

The 30-second read

$MRKBearishMed
01

Why it matters

The combined news creates mixed sentiment; the drug stop is a negative catalyst, while the court win offers a modest positive offset.

02

Market read

Primary company news with material impact on Merck's valuation and potential ripple effects across the oncology sector.

03

What to watch

Merck's dividend increase and strong Q3 sales may support the stock despite the drug halt.

Relevance 7/10Novelty 8/10Timing: after market close

Background

Merck announced the cessation of its experimental blood‑cancer drug nemtabrutinib after a Phase 3 review and reported a German court decision favoring its Keytruda patent case against Halozyme.

Company-level read

Ticker impact

$MRKBearishHigh confidence
Context

Merck stopped development of the blood‑cancer drug nemtabrutinib after a Phase 3 review, a fresh negative catalyst for the company.

Expected impact

likely modest downside as investors price in the loss of the nemtabrutinib program

Evidence & confidence

The news is a primary disclosure of a discontinued drug program, a material event for a large pharma, and no comparable offsetting catalyst outweighs the negative impact.

Market effects

May pressure other oncology drug developers as pipeline risk reassessed.

US pharma stocks could see slight pullback.

Limited to biotech/healthcare investors worldwide.

Counterpoint

The court win and strong Keytruda pipeline could cushion the impact, presenting a buying opportunity on the dip.

Key entities

  • Merck

    US‑listed pharmaceutical giant (ticker MRK).

Related articles

$MRKMed

Merck TroFuse-015 Phase 3 Meets Survival Endpoint — CASRAI

Merck announced that its Phase 3 trial of sacituzumab tirumotecan (sac-TMT) met the primary endpoint of overall survival in patients with advanced gastroesophageal adenocarcinoma. The drug showed a statistically significant improvement in survival compared to physician's choice treatments, though secondary endpoints were not met. Full results will be presented at an upcoming medical meeting. Sac-TMT is not yet approved for any use.

$MRKHighAI 9/10

Merck Buys San Diego's Cidara Therapeutics for $9.2 Billion

Merck completed its $9.2 billion acquisition of Cidara Therapeutics, gaining control of CD388, an experimental flu drug. CD388 showed 76.1% efficacy in preventing flu in healthy adults in a Phase 2b trial, but further testing is needed for high-risk groups. Merck paid $221.50 per share for Cidara, with 85.96% of shares tendered. The FDA granted CD388 Breakthrough Therapy Designation, and Phase 3 trials are ongoing.

$MRKMedAI 8/10

Sac-TMT Meets OS End Point in Pretreated Gastroesophageal Adenocarcinoma

Merck's phase 3 TroFuse-015 trial showed sacituzumab tirumotecan improved overall survival in pretreated gastroesophageal adenocarcinoma patients, meeting its primary endpoint. The trial enrolled 473 patients, comparing the drug to treatment of physician's choice. Secondary endpoints like progression-free survival were not met, but the drug's safety profile was consistent with prior studies. Merck plans to discuss the data with regulators and present it at an upcoming medical meeting.

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.